Answered

Connect with a global community of experts on IDNLearn.com. Join our community to receive prompt and reliable responses to your questions from knowledgeable professionals.

Which of the following is true regarding tumor mutational burden (TMB)?

A. TMB has been shown to be an ineffective biomarker at predicting response to immunotherapy.
B. TMB is an emerging biomarker that may be helpful in selecting patients for immunotherapy.
C. TMB is an FDA-approved test for patients with advanced NSCLC.
D. TMB is an FDA-approved test for patients with advanced melanoma.

Sagot :

GinnyAnsweridn

Final answer:

TMB is an emerging biomarker used to predict response to immunotherapy.


Explanation:

Tumor Mutational Burden (TMB) is an emerging biomarker that shows promise in selecting patients for immunotherapy. It is not an FDA-approved test for advanced NSCLC or advanced melanoma. TMB is used as a predictive biomarker to determine how well a patient will respond to treatment, especially immunotherapy.


Learn more about Tumor Mutational Burden (TMB) here:

https://brainly.com/question/786543


Your engagement is important to us. Keep sharing your knowledge and experiences. Let's create a learning environment that is both enjoyable and beneficial. Thank you for choosing IDNLearn.com. We’re committed to providing accurate answers, so visit us again soon.